A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder
نویسندگان
چکیده
BACKGROUND The prevalence of major depressive disorder (MDD) is highest in working age people and depression causes significant impairment in occupational functioning. Work productivity and work absence should be incorporated into clinical assessments but currently available scales may not be optimized for clinical use. This study seeks to validate the Lam Employment Absence and Productivity Scale (LEAPS), a 10-item self-report questionnaire that takes 3-5 minutes to complete. METHODS The study sample consisted of consecutive patients attending a Mood Disorders outpatient clinic who were in full- or part-time paid work. All patients met DSM-IV criteria for MDD and completed during their intake assessment the LEAPS, the self-rated version of the Quick Inventory for Depressive Symptomatology (QIDS-SR), the Sheehan Disability Scale (SDS) and the Health and Work Performance Questionnaire (HPQ). Standard psychometric analyses for validation were conducted. RESULTS A total of 234 patients with MDD completed the assessments. The LEAPS displayed excellent internal consistency as assessed by Cronbach's alpha of 0.89. External validity was assessed by comparing the LEAPS to the other clinical and work functioning scales. The LEAPS total score was significantly correlated with the SDS work disability score (r = 0.63, p < 0.01) and the Global Work Performance rating from the HPQ (r = -0.79, p < 0.01). The LEAPS total score also increased with greater depression severity. CONCLUSION The LEAPS displays good internal and external validity in a population of patients with MDD attending an outpatient clinic, which suggests that it may be a clinically useful tool to assess and monitor work functioning and productivity in depressed patients.
منابع مشابه
A Comparison of Emotional Schemas in Patients with Bipolar Disorders and Major Depressive Disorder in Remission and Nonclinical Population
Objective: Similarities and differences among mood disorders can help psychiatrics in their exact diagnosis and more effective treatments. Therefore, the current research sought to identify differences between patients with bipolar disorder, major depressive disorder, and nonclinical group in emotional schemas. Methods: The present research was a cross-sectional study. The research sample cons...
متن کاملThe effect of remission status on work functioning in employed patients treated for major depressive disorder.
BACKGROUND The ability to function at work is impaired in patients with major depressive disorder (MDD) but few clinical trials include occupational outcome assessments. This study examined whether symptom remission following treatment for MDD is associated with work functioning improvement. METHODS We conducted a secondary analysis of a 12-week randomized clinical trial comparing escitalopra...
متن کاملCorrelation of HbA1c and Major Depressive Disorder in Type 2 Diabetic Patients
OBJECTIVE: To evaluate the relation between major depressions and glucose control index in type 2 diabetes mellitus. MATERIALS AND METHODS: One- hundred thirty four patients with type 2 diabetes were enrolled in this study. Hamilton Rating Scale for Depression (HAM-D) and HbA1c were measured in patients. Linear mixed-model analysis was applied to determine the relation between HbA1c levels and...
متن کاملEfficacy of different doses of ketamine as a bolus in major depressive disorder
Background: Major depressive disorder is a severe, heterogeneous, common medical illness and a leading cause of disability throughout the world that poses a significant public health issue. Previous studies have shown rapid antidepressant effects following a single administration of ketamine. This study aimed to assess the impact of route of administration and dose of ketamine for the reduction...
متن کاملVortioxetine versus placebo for treatment of major depressive disorder
Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane libr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 9 شماره
صفحات -
تاریخ انتشار 2009